The U.S. Department of Health and Human Services (HHS) has delivered a significant announcement that could potentially reshape the landscape of cannabis legalization in the United States. The HHS has proposed the reclassification of cannabis, shifting it from Schedule I to Schedule III within the federal legal framework. This major news has sparked a lively debate and rekindled the conversation about cannabis reform.
This development follows President Joe Biden’s 2022 announcement, in which he proposed mass marijuana pardons and called for a thorough review of cannabis laws. This marked a notable change in the federal government’s stance on cannabis, in line with the increasing support for cannabis reform nationwide.
In a letter dated Aug. 29, 2023, the HHS formally communicated its suggestion to the Drug Enforcement Administration (DEA) to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). While the DEA holds the ultimate authority for this decision, the HHS’s scientific assessment and the growing political backing for cannabis reform may significantly sway the DEA’s final ruling.
The White House has made it clear that the rescheduling process is an independent endeavor led by the HHS and the Department of Justice (DOJ), guided by solid scientific evidence. This underscores the administration’s dedication to making decisions grounded in factual information and rigorous analysis.
Veriheal has satisfied hundreds of thousands of patients nationwide
The HHS’s recommendation represents a historic milestone for the cannabis industry, with profound implications:
To further understand the importance of this recommendation, let’s break down the differences between Schedule I and Schedule III drugs.
Currently, cannabis is classified as a Schedule I drug at the federal level. This classification indicates that it’s considered to have a high potential for abuse, lacks recognized medical uses, and is deemed unsafe for any form of supervised medical administration.
If cannabis were rescheduled to Schedule III, it would be acknowledged as having a lower potential for abuse compared to Schedule I substances. Furthermore, Schedule III drugs are recognized to have established medical applications, and their misuse typically results in moderate physical dependence or high psychological dependence.
The potential reclassification of cannabis to Schedule III could mark a significant turning point in the ongoing cannabis legalization debate. Watching how this recommendation unfolds in the coming months promises to be a fascinating development in the world of cannabis reform. Stay tuned for updates on this transformative shift.
Another idiotic thing that people think will be great. Worst thing that can be done as it will be taken away from everyone and turned into a bs medicine. Home grows will for sure be done with and big pharma will own it. Don’t vote for legalization ever! Don’t fall for it. Always read the fine print.
It’s a baby step. A good step, long overdue, but a tiny one. “Half measures availed us nothing”, to purloin a phrase from a different context. A bit like trying to cross a 15 foot wide ditch in two 8-foot jumps. Progress, nevertheless.
As of now, 15 states have legalized adult use of med and rec, and when a state legalizes recreational use of cannabis, people tend to stop getting their mmj cards. But cannabis consumers who opt not to get a MMJ card are missing out on a bunch of benefits like paying lower costs, the ability…
Suddenly, the world of magic mushrooms is almost as complicated as that of learning about cannabis. Shrooms or “magic” mushrooms have gained traction as a hallucinogenic therapeutic application for several different mental health circumstances such as depression and migraines—particularly when microdosing. It’s not just liberty caps anymore, folks. There are many different varieties and types…
Edibles are arguably one of the best means of recreational cannabis consumption—you get to eat a treat AND experience a long-lasting high. But it’s easy to end up dealing with some unwanted side effects due to the variability in the onset of these THC-packed goodies, which come in the form of brownies, cookies, gummies, chocolate,…
According to a new study published by the University of New Mexico (UNM) in the prestigious journal Frontiers in Pharmacology, researchers have unveiled a significant correlation between the sensation of “feeling high” and the relief of medical symptoms among cannabis patients. This landmark study probes uncharted territories, challenging pre-existing assumptions and opening new avenues for…
A survey illustrates psychedelics’ rapid rise, Herer Brands sues Daniel Herer, and Hulkamania comes to cannabis. Let’s dive into this week’s canna-news. Psychedelic Use Reaches Record High A new national survey conducted by Monitoring The Future found that psychedelic use is at an all-time high amongst U.S. adults. Conducted in 2022, the survey included approximately…
